Abstract: An oxo-pyridine fusion ring compound of chemical formula 1 or a pharmaceutically acceptable salt thereof effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines.

Abstract: The present invention provides a spinal correction device comprising: a pedicle screw comprising a seating part having a pair of first slits formed opposite to each other, and a screw part disposed at one side of the seating part so as to be implanted into a bone; an extender having a pair of second slits for guiding a rod so as to seat same in the seating part, and detachably fastened at one side thereof to the outer surface of the seating part; a reduction body detachably fastened to the other side of the extender; and a rod reducer arranged to pass through the reduction body and the extender so as to fix the rod placed in the pair of second slits by pressing the rod against the seating part.

Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells. In the present invention, it was confirmed that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells effectively killed cells expressing CD22.

Abstract: An object of the present invention is to provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity, and a method for producing the same. The present invention can provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity by drying a methanol solvate crystal of eucomic acid.

Abstract: A supplement supply support device includes an acquisition unit configured to acquire information pertaining to training of a user, and a supplement determination unit configured to determine supply conditions of a supplement according to the information pertaining to training of a user on the basis of a recommendation algorithm for recommending supply conditions of a supplement in accordance with information pertaining to training.

Abstract: The present invention relates to a pharmaceutical composition for administration in combination with a drug that causes acidosis. Acidosis occurs due to disrupted acid-base balance caused in a case where a large amount of acid is produced and accumulated in the body. There are many cases where acidosis occurs as a side effect associated with drugs for treating various diseases, which poses problems. The pharmaceutical composition of the present invention not only allows the intended purpose, for which a drug that causes acidosis is administered, to be maintained but also has a remarkable effect in decreasing the concentration of acid accumulated in an organism due to administration of the drug that causes acidosis. Thus, the pharmaceutical composition is expected to be widely used in the fields of medicine and health.

Abstract: The present invention relates to a method of manufacturing a hyaluronate film and a hyaluronate film manufactured thereby, and more particularly to a method of manufacturing a hyaluronate film through a solvent-casting process or using an automatic film applicator that facilitates mass production and to a hyaluronate film manufactured thereby, which is useful as a mask pack for cosmetics, a patch for medicaments and medical devices, a film-type adhesion inhibitor, etc. Unlike conventional liquid products, the hyaluronate film according to the present invention has a dry surface and thus entails no concern about microbial contamination, is easy to produce/manage/distribute/use, and has superior mechanical properties, whereby it can be utilized for various applications such as packs, patches, artificial skin and the like for cosmetics, medicaments, and medical devices.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating acidosis. The pharmaceutical composition has a remarkable effect in decreasing the concentration of acid accumulated in an organism and thus is expected to be widely used in the fields of medicine and health.

Abstract: The present invention relates to a probiotics composition containing: lactic acid bacteria powder comprising lactic acid bacteria selected from the group consisting of Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus rhamnosus; a mushroom extract; and a fructooligosaccharide.

Abstract: A zinc-alpha-2-glycoprotein (ZAG) protein-derived peptide according to the present invention shows an expression reducing effect of various immune factors shown in acute or chronic atopic dermatitis, and has a decreased immune response and decreased IgE expression and thus may be used to prevent, treat or improve xeroderma or an abnormal skin barrier function such as atopic dermatitis, an allergic disease or inflammation.

Abstract: The present invention provides a novel phytochemical-fructooligosaccharide conjugate having a structure in which a phytochemical in the form of phenolic acid is conjugated to a portion of saccharides constituting a fructooligosaccharide backbone. Compared to corresponding phenolic acid phytochemicals, the novel phytochemical-fructooligosaccharide conjugate according to the present invention is hardly decomposed under oral-gastrointestinal transit conditions such that most of the phytochemical-fructooligosaccharide conjugate may reach the large intestine. Thus, the novel phytochemical-fructooligosaccharide conjugate has good bioavailability in the large intestine when orally administered.

Abstract: The present invention relates to a method for treating or preventing benign prostatic hyperplasia comprising administering an effective amount of a composition consisting essentially of an Aucklandiae Radix extract as an active ingredient to a subject in need of treating or preventing benign prostatic hyperplasia.

Abstract: An object of the present invention is to provide a crystal of L-alanyl-L-glutamine having a low loose specific volume, and a method for producing the same. The present invention relates to a crystal of L-alanyl-L-glutamine in which the loose specific volume is 5.0 mL/g or less, and a method for producing the same.

Abstract: The present invention relates to a crystal of glutathione trisulfide dihydrate and a method for producing the same. According to the present invention, for example, the crystal can be provided by concentrating an aqueous solution in which glutathione trisulfide is dissolved and collecting the precipitated crystal of glutathione trisulfide dihydrate. In addition, the present invention relates to a simple method for producing polysulfide in an aqueous solvent using thiosulfate without using hydrogen sulfide, by stirring an aqueous solution in which a compound having a thiol group or a disulfide bond and thiosulfate are dissolved or by leaving the aqueous solution to stand.

Abstract: The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.

Abstract: An object of the present invention is to provide a crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties, and a production method thereof. According to the present invention, the crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties can be obtained by precipitating the crystal of cytidine diphosphate choline in an aqueous solution in which cytidine diphosphate choline is dissolved, collecting the precipitated crystal of cytidine diphosphate choline, and washing the collected crystal of cytidine diphosphate choline with an aqueous solution containing an organic solvent other than methanol in which a water content is 5% to 50% by volume.

Abstract: A new use of exosomes extracted from mesenchymal stem cells derived from a healthy individual co-cultured with melatonin or a culture solution thereof, for the treatment of chronic kidney disease is disclosed. A pharmaceutical composition containing the exosomes extracted from mesenchymal stem cells derived from a healthy individual co-cultured with melatonin or a culture solution thereof as an active ingredient and a method for preparing the pharmaceutical composition are disclosed. The exosomes promote the proliferation of mesenchymal stem cells derived from a chronic kidney disease patient or increase the survival rate of the patient.

Abstract: The present invention provides a spinal correction device comprising: a pedicle screw comprising a seating part having a pair of first slits formed opposite to each other, and a screw part disposed at one side of the seating part so as to be implanted into a bone; an extender having a pair of second slits for guiding a rod so as to seat same in the seating part, and detachably fastened at one side thereof to the outer surface of the seating part; a reduction body detachably fastened to the other side of the extender; and a rod reducer arranged to pass through the reduction body and the extender so as to fix the rod placed in the pair of second slits by pressing the rod against the seating part.

Abstract: According to the present invention, theanine can efficiently be produced without exogenously adding ethylamine and without accumulation or leftover of ethylamine as a byproduct, by using a microorganism having enhanced activity to produce ethylamine with acetaldehyde and alanine as substrates and having enhanced activity of ?-glutamylmethylamide synthetase or glutaminase.